-
Microsoft Updates Xbox PC App with 60% Faster Startup and Redesigned Interface
-
Cause of Death Revealed for 'Ellen' Producer Matthew Wright
-
Early Polar Vortex Disruption Creates Uncertain Winter Outlook for Pennsylvania
-
Edmund Richardson Wins Baillie Gifford Prize for 'Alexander' Biography
-
Pakistan Demands Grant-Based Climate Finance at COP31 to Avoid Debt Trap
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
E Pellicci Pop-Up at Selfridges Brings Back Nostalgic School Cake
-
Ryanair Flight from Rome Makes Emergency Landing in Lisbon After Bomb Threat
-
Coronation Street's Debbie Webster Steps Down as Dementia Storyline Intensifies
Featured
Last news
Premiere San Antonio Presented by SalonCentric Achieves Record-Breaking Success in Historic Partnership Year
30% Attendance Growth and First-Ever Presenting Partnership Mark Milestone Event for the Southwest Professional Beauty Community
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million todaySecured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target PharmaCoverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flowsDivision targeted to generate over $10 million in recurring annual profit at full capacity
Renew Health + Recovery Purchases Assets of Aware Recovery Care
Renew to operate in-home substance use disorder treatment across 11 states
2026 Is Now the Most Destructive Wildfire Season in a Decade - And It's Not Over Yet
With over 8.3 million acres burned and fire season still active, Fire Help Center urges affected Americans to understand their legal rights before the window to act closes.
Indian Bridal Fashion Takes Center Stage as Industry Leaders David's Bridal and KYNAH Deepen Partnership with Exclusive Collection
Building On The Success Of The Initial Partnership, The New Co-Designed Collection Brings The Artistry And Craftsmanship Of Indian Bridal Fashions To More Brides And Wedding Guests Than Ever Before
UTMD Announces Self-Tender for 20% of Its Shares
SALT LAKE CITY, UT / ACCESS Newswire / September 15, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces today that it intends to repurchase at a price of $75.00 per share up to 650,000 of its shares, if tendered and not withdrawn by stockholders on or before October 7, representing approximately 20% of its currently outstanding shares. The offering price is 17% higher than the average daily closing price of UTMD shares trading in the open market during the last twelve months, and 21% higher than the average daily closing price of UTMD shares trading during the last two years. The highest intraday trading price during the last two years was $75.75.
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") is scheduled to start next week at an Ebola Treatment Center in the Ituri province.
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program to provide safer opioids for severe pain as well as a substantial background on complex pain, specifically Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford also outlined the novel approach to CRPS, the platform that Ensysce recently added to its toolbox through the acquisition of Cy Biopharma.
Who Does the Best Facelift in Oklahoma?
The Best Facelift in Oklahoma Is Performed by Dr. Erik Nuveen at Cosmetic Surgery Affiliates
Medical Care Technologies Inc. (OTCID:MDCE) Details StrainScan Pro's On-Device Visual Inspection Pipeline for iPad Air
Image Acquisition, Contextual Indexing, Differential Analysis and Exception Routing Designed to Move Quality Decisions to the Point of Inspection
Jaguar Health, Inc. Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026
ALTANFEETHI Expands Business, Targets SAR 4.2 Billion Market Value
ALTANFEETHI Expands Business
374Water Completes $600,000 Waste Destruction Services in St. Cloud, MN
Four-phase, multi-feedstock campaign concludes; PFAS destruction results to be analyzed and released in the coming weeks
Study Finds Healthcare Concern Jumps From 31% to 74% After Federal Debt Connection Is Explained
Black Book's national consumer study finds nearly one-third would borrow, delay care or skip treatment if annual household healthcare costs increased by $1,000; full report available complimentary to industry stakeholders and media.
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 15
InterContinental Hotels Group PLC (the "Company")Purchase of own shares
US judge postpones new visa rules for foreign students, journalists
A US federal judge on Monday postponed implementation of a Trump administration policy that would impose stricter limits on how long foreign students and journalists can study or work in the United States.
UN calls for 'urgent action' to rein in AI in face of 'unprecedented risks'
The United Nations rights chief called Monday for countries and "frontier" artificial intelligence companies to act urgently to rein in a technology he warned posed "unprecedented risks".
Saudi football body vows action against Jota chants, Ronaldo urges life ban
Saudi Arabian football authorities promised to take action and Cristiano Ronaldo called for life bans after rival fans taunted Al-Hilal's Ruben Neves about the death of Diogo Jota, his friend and former Portugal team-mate.
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026
DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and nine months ended July 31, 2026 were approximately $2.3 million and $7.3 million, respectively, representing increases of approximately $0.4 million and $0.5 million compared to the same periods last year.
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stockPositions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets.CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorptionIntellectual property owned outright, with patent applications advanced into the United States, Europe, Australia and CanadaAddresses a global weight management market projected to reach $562.2 billion by 2033 (14.2% CAGR) - set against a broader tokenized real-world-asset market projected to reach $18.9 trillion by 2033
Amid Growing Physician Shortages, Desert Oasis Healthcare Expands Access to Local Care
As communities nationwide face growing physician shortages and challenges accessing care, DOHC offers more than 60,000 members and patients access to nearly 70 primary care physicians and 31 specialty departments.
Trustpoint Xposure, the First AEO-Certified PR Agency , Announces October 1st Unveiling of Game-Changing AI Agent Suite That Is Already Helping Clients Get More Leads Build Trust and Get Recommended by AI
The first AEO-certified PR agency in the United States sets an October 1st launch date for its AI Agent Suite, a collection of purpose-built AI agents that automate lead generation, trust building, authority growth, and AI recommendation acquisition for professional brands across every major category
AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 2026
One unified Enterprise Imaging platform brings workflow, streaming, cloud, and AI together to help clinicians stay focused and imaging organizations reduce complexity.
MDCE Subsidiaries Execute First Fanatics / Topps Transaction: Infinite Auctions Sells, Real Game Used Authenticates (OTCID:MDCE)
Subsidiaries Positioned to Supply and Authenticate Products for One of the World's Largest Sports Collectibles Platforms
SKIL introduces PWRCORE GO(TM): five grab-and-go tools designed to make everyday DIY faster and easier
NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / SKIL®, a trusted leader in power tools with more than 100 years of innovation, has launched its new PWRCORE GO™ product line, a collection of five compact, easy-to-use tools designed to simplify everyday DIY tasks. PWRCORE GO™ tools combine grab-and-go portability, intuitive features, convenient USB-C charging and the right amount of performance for homeowners, renters and DIYers to tackle common tasks quickly and confidently.
New to The Street Signs Media Partnership with Total Sync Network Inc., Creator of SyncMeOn
Integrated campaign will introduce SyncMeOn's restaurant-supplier marketplace to business audiences through television, YouTube, iconic outdoor billboards, commercials and accredited-investor events
Dr. Thomas Pane Obtains Hospital Privileges at Holy Cross in Fort Lauderdale
Double board-certified plastic surgeon adds a hospital-based surgical option for patients whose medical circumstances call for one.
Chervon Names Jeffrey P. Campbell Senior Vice President of Industrial Commercial Sales
NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Jeffrey P. Campbell joins Chervon as Senior Vice President of Industrial Commercial Sales effective Monday, September 14, 2026, reporting to CEO Joe Galli.
Chervon Names Matthew H. DeFeo as Senior Vice President of Sales, Training and Recruiting
Accomplished Power Tools and Outdoor Power Equipment industry leader brings decades of experience in sales leadership, talent recruitment and development, channel management, and key account alignment
RF Industries Reports Third Quarter Fiscal Year 2026 Financial Results
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / RF Industries, Ltd. (NASDAQ:RFIL), a national manufacturer and marketer of interconnect products and systems, today announced financial results for the third quarter of fiscal year 2026 ended July 31, 2026.
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," being held today, Monday, September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.